Skip to main content
. 2019 Jul 30;2(6):402–413. doi: 10.1021/acsptsci.9b00045

Figure 2.

Figure 2

MTA sensitivity in glioblastoma cells. (a) Schematic of relative drug sensitivity metrics calculated from a dose–response curve fitted to a relative cell count. (b) Proliferation rates of glioblastoma cell lines were determined with the IncuCyte platform and CellCounter + + online tool. (c) Schematic of grow inhibition (GR) metrics from a dose–response curve fitted to GR values. Relative and GR metrics for colchicine (d), nocodazole (e), tivantinib (f) and CMPD1 (g) were calculated from dose responses determined with CellTiter-Blue viability assay after 5 days of drug treatment and proliferation rates using the GRcalculator tool. Data are mean ± SEM (n = 3). All values are listed in Tables S3–S6.